GlassScriptPhysician profile
Sara Mcgowan
NPI 1699047969
$4,040.45
in general payments reported to CMS, 2019-2025
28 companies · $1,696 in 2025
The $1,696 reported for 2025 was more than what 89% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $852 · 2022: $210 · 2023: $172 · 2024: $1,110 · 2025: $1,696.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,979.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,978.82 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $672.40 | 2021-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $546.17 | 2024-2025 | Caplyta |
| Braeburn INC. | $380.44 | 2024-2025 | Brixadi |
| Otsuka America Pharmaceutical, INC. | $329.87 | 2024-2025 | Abilify Asimtufii, Rexulti, Abilify Maintena |
| Indivior INC. | $296.36 | 2023-2025 | Sublocade |
| Alkermes, INC. | $291.74 | 2024-2025 | Vivitrol, Aristada, Lybalvi |
| Janssen Pharmaceuticals, INC | $272.52 | 2021-2025 | Invega Sustenna, Invega Trinza, Spravato |
| Neurocrine Biosciences, INC. | $225.34 | 2023-2025 | Ingrezza |
| Novo Nordisk INC | $214.27 | 2021-2022 | |
| Pfizer INC. | $177.42 | 2021-2022 | |
| Teva Pharmaceuticals USA, INC. | $97.25 | 2024 | Uzedy |
| Glaxosmithkline, LLC. | $57.29 | 2021-2023 | Trelegy Ellipta |
| Lilly USA, LLC | $57.17 | 2021 | |
| Vanda Pharmaceuticals INC. | $51.40 | 2024-2025 | Hetlioz, Fanapt |
| Lundbeck LLC | $46.09 | 2025 | Rexulti |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Uswm, LLC | $45.42 | 2023 | Zimhi, Lucemyra |
| Merck Sharp & Dohme LLC | $37.51 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $35.82 | 2021 | |
| Orexo US, INC. | $29.95 | 2024 | Zubsolv |
| Axsome Therapeutics, INC. | $24.67 | 2025 | Auvelity |
| Boehringer Ingelheim Pharmaceuticals, INC. | $24.46 | 2021 | |
| Antares Pharma, INC. | $21.68 | 2021 | |
| Althera Pharmaceuticals LLC | $21.61 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $21.36 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $19.90 | 2021 | |
| Amarin Pharma, INC. | $16.25 | 2021 | |
| Supernus Pharmaceuticals, INC. | $14.03 | 2021 | |
| Abbott Laboratories | $12.06 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sara Mcgowan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.